Skip to content

My child has ADHD: Medication or Meditation?

Medication or Meditation? Mindfulness training versus medication in the treatment of childhood ADHD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22179
Enrollment
120
Registered
2013-10-11
Start date
2014-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

Medication (methylphenidate
Ritalin): 8 weeks of optimal daily dose of Ritalin, followed by a second period of 8 weeks of optimally dosed Ritalin. Parents receive 2-3 standardized parental guidance/psycho education sessions. Mi

Sponsors

University of Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Child aged 9-18 years. - DSM classification of ADHD. - ADIS-C is administered to verify ADHD diagnosis. - (Estimated) IQ > 80. - At least one parent is willing to participate in the Mindful Parenting training.

Exclusion criteria

Exclusion criteria: - (Estimated) IQ < 80. - Suffering from suicidal ideation, psychosis or schizophrenia. - Co-morbid autism or Conduct Disorder. - Current or past use of methylphenidate (Ritalin). - Participation in current active other psychological intervention.

Design outcomes

Primary

MeasureTime frame
Attention, hyperactivity, and impulsivity in the child (i.e., DBDRS, CBCL, TRF, YSR, BRIEF, TEA-Ch, D2, TOF etc.), percentage of children free of of a DSM classification (i.e., ADIS).

Secondary

MeasureTime frame
Symptoms of anxiety, depression, sleeping problems, social functioning, child and parental quality of life, parental symptomatology, parental mindfulness and stress (i.e., ASR, PS, NOSIK, CSBQ, PSS, CSRQ, PSQI, SVK, WHO-5, FFMQ, IM-P etc.). In addition cost-effectiveness of both treatments is assessed.

Contacts

Public ContactEsther Bruin, de

Nieuwe Prinsengracht 130

e.i.debruin@uva.nl0031-20-525-1262

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)